Early NETRF-funded research identifies a potential prognostic biomarker to help physicians predict neuroendocrine cancer outcomes.

NETRF’s Director of Research John Kanki, PhD, provides an update on the status of ongoing NETRF-funded research studies during COVID-19.

NETRF-funded research of miniature replicas of human organs is recognized with a Presidential Award for Basic Science at ENETS, a leading international meeting of NET scientists.

NETRF reports progress in the development of neuroendocrine tumor cell lines to help eliminate a decades-old obstacle in laboratory research. To stimulate progress in NET cell lines, NETRF established a Cell Line Prize, funded cell line research, and launched a collaboration with a nationally known research institute. Each of these initiatives has succeeded in establishing NET cell lines.

NETRF welcomes five new members to its Board of Scientific Advisors, a volunteer council of highly distinguished medical and research leaders who share NETRF’s commitment to advancing the diagnosis and treatment of neuroendocrine cancer.